| Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. | |
| | |
MedLine Citation:
|
PMID: 8555936 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To test whether use of combined oral contraceptives containing third generation progestogens is associated with altered risk of myocardial infarction. DESIGN: Matched case-control study. SETTING: 16 centres in Austria, France, Germany, Switzerland, and the United Kingdom. SUBJECTS: Cases were 153 women aged 16-44 with a myocardial infarction event. Controls were 498 women (at least 3 controls per case) unaffected by myocardial infarction who were matched with their corresponding case for age and for hospital or community setting within four months of the index infarction. MAIN OUTCOME MEASURES: Odds ratios derived with stratified analyses and unconditional logistic regression to adjust for potential confounding variables. RESULTS: The estimated odds ratio for myocardial infarction of third compared with second generation oral contraceptives among all 651 study subjects was 0.36 (95% confidence interval 0.1 to 1.2) (P = 0.11). The odds ratio for the United Kingdom and Germany alone was 0.45 (0.1 to 1.8) (P = 0.26). Other odds ratios for the five countries were 3.1 (1.5 to 6.3) (P = 0.003) for use of second generation products v no current use and 1.1 (0.4 to 3.4) (P = 0.9) for use of third generation products v no current use. Among the confounding variables the independent contribution of smoking (for which adjustment was made in the above estimates) proved to be important (10.1 (5.7 to 17.9), P < 0.001). CONCLUSION: An odds ratio of 0.45 with wide confidence intervals shows that third generation oral contraceptives compared with second generation products are associated with a reduced risk of myocardial infarction or with no difference. This finding from an interim analysis should be interpreted with extreme caution. However, the excess risk of venous thromboembolism associated with the use of third generation products may be balanced by the reduced risk of myocardial infarction associated with the same products. |
| | |
Authors:
|
M A Lewis; W O Spitzer; L A Heinemann; K D MacRae; R Bruppacher; M Thorogood |
Related Documents
:
|
16169366 - Impact of beta-blocker therapy at discharge on long-term mortality after primary angiop... 16209986 - Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary art... 19576336 - Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertensio... 20851476 - Effect of an invasive strategy on in-hospital outcome and one-year mortality in women w... 20965876 - Urinary 8-hydroxy-2'-deoxyguanosine reflects symptomatic status and severity of systoli... 19586956 - Melanocyte pigmentation stiffens murine cardiac tricuspid valve leaflet. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: BMJ (Clinical research ed.) Volume: 312 ISSN: 0959-8138 ISO Abbreviation: BMJ Publication Date: 1996 Jan |
Date Detail:
|
Created Date: 1996-02-28 Completed Date: 1996-02-28 Revised Date: 2010-03-24 |
Medline Journal Info:
|
Nlm Unique ID: 8900488 Medline TA: BMJ Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 88-90 Citation Subset: AIM; IM |
Affiliation:
|
Potsdam Institute of Pharmacoepidemiology and Technology Assessment (PIPTA), Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Austria / epidemiology Case-Control Studies Contraceptives, Oral, Combined / adverse effects* Contraceptives, Oral, Synthetic / adverse effects* Female France / epidemiology Germany / epidemiology Great Britain / epidemiology Humans Logistic Models Middle Aged Myocardial Infarction / chemically induced*, epidemiology Odds Ratio Risk Factors Switzerland / epidemiology |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptives, Oral, Combined; 0/Contraceptives, Oral, Synthetic |
| Comments/Corrections | |
Comment In:
|
BMJ. 1996 Jan 13;312(7023):68-9
[PMID:
8555921
]
BMJ. 1996 Mar 2;312(7030):577-8 [PMID: 8595303 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international c...
Next Document: Large outbreak of Salmonella enterica serotype paratyphi B infection caused by a goats' milk cheese,...